Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across research and clinical applications including cancer and liquid biopsy studies.
Stilla’s groundbreaking Crystal Digital PCR™ solution, the naica® system, is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Moreover, Stilla provides digital PCR kits out-of-the-box, as well as custom assay design services in order to help researchers detect and quantify genes across multiple cancer indications through a liquid biopsy test.
